Introduction of new oral antiplatelet drugs in myocardial infarction hospital network: initial experience

Abstract

New oral antiplatelet drugs (prasugrel, ticagrelor) are recommended in the current European Society of Cardiology guidelines for the management of patients presenting with ST-segment elevation myocardial infarction (STEMI) [1]. However, in many STEMI hospital networks administration of a 600-mg clopidogrel loading dose before or during transfer to cathlab… (More)
DOI: 10.1007/s11239-013-0930-z

2 Figures and Tables

Topics

  • Presentations referencing similar topics